708 Quince Orchard Road
Mark Gessler, CEO
Gene Logic provides scientists with surveys of human gene expression information. Its GeneExpress Suite of gene expression information consists of three integrated modules: the BioExpress Module, the ToxExpress Module and the PharmExpress Module. Gene Logic also offers solution sets that include DataSuites, MultiSuites or CustomSuites. All are derived from pathologist-reviewed tissue samples and are analyzed using microarrays and Gene Logic’s READS technology. Gene Logic’s solution sets are enhanced by its bioinformatics solution, the GeneExpress2000 data mining, visualization and analysis software tools. Gene Logic also collaborates with customers in discovery research programs.
Gene Logic has said its goal is to be the premier supplier of biocontent and bioinformatics solutions.
In December 2001, Gene Logic established a genomic database agreement with Aventis Pharmaceuticals Inc., the U.S. pharmaceuticals division of Frankfurt, Germany-based Aventis Pharma AG. Through the agreement, Aventis will establish a CustomSuite subscription, gaining access to biosamples across a specific group of organ types gathered from the BioExpress Module of the GeneExpress Suite. Financial details of the database agreement were not disclosed.
In July 2001, the company completed a spin-off of its Flow-thru Chip technology into a new company, MetriGenix Inc. MetriGenix secured $15 million in initial financing to further develop and commercialize the technology.
Gene Logic said in June 2001 it had invested in and initiated a research collaboration with Metabometrix Ltd., of London, as part of Gene Logic’s efforts to accelerate the growth of the content component of its biological-information products. Financial terms of the investment were not disclosed.
In January 2001, Incyte Genomics Inc., of Palo Alto, Calif., and Gene Logic settled litigation related to patent infringement lawsuits filed by Incyte. Through the settlement, the lawsuits were dismissed and Gene Logic now has a nonexclusive license to practice the technology described in the patents. Specific settlement and financial terms were not disclosed.
Customers include the following: American Home Products, AstraZeneca Pharmaceuticals Inc., Avalon Pharmaceuticals Inc., Aventis Pharmaceuticals Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Genaissance Pharmaceuticals Inc., Genentech Inc., GlaxoSmithKline plc, IDEC Pharmaceuticals Inc., Japan Tobacco Inc., LG Chemical Ltd., NV Organon, NeuralStem BioPharmaceuticals Inc., Pfizer Inc., Procter & Gamble Pharmaceuticals, Psychiatric Genomics Inc., PsychoGenics Inc., Sankyo Co. Ltd., Sumitomo Pharmaceuticals Co. Ltd. and UCB Research.
Strategic partners include Amersham Pharmacia Biotech KK, Genaissance Pharmaceuticals Inc., Invitrogen Corp. and Metabometrix Inc.